Future studies should focus on developing specific KCTD17 inhibitors and advancing the clinical translation of SERPINA3-basaed therapies, which could provide a novel and effective treatment approach for liver fibrosis in patients with MASH. This evidence concerns the gene KCTD17 and metabolic dysfunction-associated steatohepatitis.